RxDoctor Payments Data

Marco Caccamo, DO

Advanced Heart Failure and Transplant Cardiology · Morgantown, WVNPI 1164696530

Payments from drug & device makers

$749,739in general payments, 2019–2025

Across 156 payments — averaging $4806.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$542K
  • Janssen Research & Development, LLC$145K
  • Bayer$36K
  • Vifor (international) Ltd.$16K
  • Actelion Pharmaceuticals US, Inc.$11K
  • Abbott$290
  • plus $242 from 3 others

What the payments were for

  • Consulting fees$17,13523%
  • Speaking & faculty fees$49,79866%
  • Travel & lodging$6,2598%
  • Food & beverage$2,6063%
  • Education$990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in West Virginiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$75,649
Medicare patients
2,401
Services billed
3,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AdempasRiociguat41$563,837
OpsumitMacitentan43$539,794
UptraviSelexipag16$397,502
Tyvaso DpiTreprostinil12$281,578
Ambrisentan58$165,867
EntrestoSacubitril/Valsartan120$113,872
JardianceEmpagliflozin77$83,048
AdcircaTadalafil12$48,663
EliquisApixaban46$46,626
FarxigaDapagliflozin Propanediol24$23,313
Tacrolimus18$6,790
Sildenafil Citrate44$4,253
Mycophenolate Mofetil22$1,986
Eplerenone15$1,165
Potassium Chloride45$961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$10,726$937,29659 claims
BayerAdempas$35,672$563,83741 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in West Virginiaon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Morgantown

Where these figures come from

Is this you, or does something look wrong? →